贝伐单抗在人脑胶质母细胞瘤抗血管生成中的研究进展  

Research progress of Bevacizumab in human glioblastoma anti-angiogenesis

作　　者：徐阳 袁凡恩 杨雪[1] 杨吉安[1] 刘宝辉[1] 陈谦学[1] XU Yang, YUAN Fan＇en, YANG Xue, YANG Ji＇an, LIU Baohui, CHEN Qianxue(Department of Neurological Surgery, Renmin Hospital of Wuhan University, Hubei Province, Wuhan 430060, Chin)

机构地区：[1]武汉大学人民医院神经外科,湖北武汉430060

出　　处：《中国医药导报》2018年第15期43-46,58,共5页China Medical Herald

摘　　要：胶质母细胞瘤是成人中枢神经系统最常见的原发性恶性肿瘤。血管生成是其重要特征之一,而血管内皮生长因子在其中发挥重要作用。贝伐单抗能够特异性地阻止血管内皮生长因子与其受体的结合,从而抑制肿瘤的血管生成,使肿瘤血管正常化实现抗肿瘤作用。但是在初诊及复发的脑胶质瘤患者中治疗效果不够满意,甚至还有耐药现象。本文就血管生成机制、贝伐单抗的作用机制及近年来临床试验和耐药机制的研究进展展开综述,以期总结目前抗血管治疗的研究成果,并预测下一步的研究方向。Glioblastoma is one of the most common primary malignant tumors in the central nervous system of adults.Angiogenesis is one of the most important hallmarks of glioblastoma, and vascular endothelial growth factor plays a key role in this process. Bevacizumab is a monoclonal antibody that can specifically prevent the combination of vascular endothelial growth factor and its receptor, thereby inhibiting the formation of tumor blood vessels and normalizing the tumor blood vessels to achieve anti-tumor effect. However, the effects of Bevacizumab in newly diagnosed and recurrent glioblastoma are not as satisfied as expected, furthermore, some cases occurred resistance. This paper reviews the research progress of the mechanism of angiogenesis, mechanism of Bevacizumab and its clinical trails and resistance mechanism in recent years, hoping to summarize the research achievements of anti-vascular therapy, and predict the next research direction.

关 键 词：胶质母细胞瘤 贝伐单抗 血管生成 抗血管生成 血管内皮生长因子 耐药性 

分 类 号：R739.41[医药卫生—肿瘤]